Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Other Operating Expenses (2020 - 2025)

Kiora Pharmaceuticals' Other Operating Expenses history spans 6 years, with the latest figure at $4.1 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 722.84% year-over-year to $4.1 million; the TTM value through Dec 2025 reached $24015.0, down 99.21%, while the annual FY2025 figure was -$3.7 million, 97.05% down from the prior year.
  • Other Operating Expenses reached $4.1 million in Q4 2025 per KPRX's latest filing, up from -$2.3 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $4.1 million in Q4 2025 to a low of -$2.3 million in Q3 2025.
  • Average Other Operating Expenses over 5 years is $551510.6, with a median of $179000.0 recorded in 2022.
  • Peak YoY movement for Other Operating Expenses: surged 1296.94% in 2022, then tumbled 467.7% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $4.0 million in 2021, then crashed by 76.19% to $950000.0 in 2022, then plummeted by 86.69% to $126454.0 in 2023, then skyrocketed by 293.99% to $498212.0 in 2024, then skyrocketed by 722.84% to $4.1 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Other Operating Expenses are $4.1 million (Q4 2025), -$2.3 million (Q3 2025), and -$640633.0 (Q2 2025).